TOP > 外国特許検索 > FUSION PROTEIN OR CONJUGATED PROTEIN, INTRACELLULAR DELIVERY CARRIER, PARTIAL PEPTIDE, CELL MEMBRANE PERMEATION ENHANCER, DNA, AND VECTOR

FUSION PROTEIN OR CONJUGATED PROTEIN, INTRACELLULAR DELIVERY CARRIER, PARTIAL PEPTIDE, CELL MEMBRANE PERMEATION ENHANCER, DNA, AND VECTOR UPDATE 新技術説明会

外国特許コード F170009131
整理番号 P1-2554,S2017-0182-N0
掲載日 2017年7月20日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP066455
国際公開番号 WO 2016199674
国際出願日 平成28年6月2日(2016.6.2)
国際公開日 平成28年12月15日(2016.12.15)
優先権データ
  • 特願2015-118432 (2015.6.11) JP
発明の名称 (英語) FUSION PROTEIN OR CONJUGATED PROTEIN, INTRACELLULAR DELIVERY CARRIER, PARTIAL PEPTIDE, CELL MEMBRANE PERMEATION ENHANCER, DNA, AND VECTOR UPDATE 新技術説明会
発明の概要(英語) The present invention addresses the problem of providing: a fusion protein or conjugated protein having excellent cell membrane permeability, containing a partial peptide derived from human, and suitable for intracellular delivery; an intracellular delivery carrier comprising such a fusion protein or conjugated protein; a partial peptide; a cell membrane permeation enhancer comprising the partial peptide; DNA; and a vector. The fusion protein or conjugated protein has a partial peptide comprising at least seven successive amino acid residues of an amino acid sequence encoded by a predetermined DNA, and a ligand directly or indirectly bound to the partial peptide and having the capability of binding to cell surfaces. The ligand is preferably an antibody. The intracellular delivery carrier comprises the fusion protein or conjugated protein. The cell membrane permeation enhancer comprises the partial peptide.
従来技術、競合技術の概要(英語) BACKGROUND ART
In recent years, and reduce the side effects or drug overdose, safely, and, effectively acts as a means for administering the drug, the drug delivery system (Drug delivery system: DDS) various studies on, has been developed.
Using this DDS, various agents could be delivered to a cell while attempts have been made for, for example, as a protein or the like of the biopolymers, low permeability of the drug in the cell membrane is also present.
Therefore, such a cell-membrane permeable low agent, may be delivered efficiently into cells has been required and, as a technology to achieve, in recent years, a cell-membrane permeable peptide has attracted attention.
For example, as a cell-membrane permeable peptide, transcription factor HIV TAT peptide has been known (see Patent Document 1).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KEIO UNIVERSITY
  • 発明者(英語)
  • SUDO, Kei
  • NIIKURA, Keisuke
  • DOI, Nobuhide
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
参考情報 (研究プロジェクト等) Doi Lab @ Dept Biosci Info, Keio Univ
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記問合せ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close